+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Oncology Drug Market - By Therapeutic Models, By Cancer Type, and By Region: Global Industry Perspective, Comprehensive Analysis and Forecast 2019 - 2026

  • ID: 5143798
  • Report
  • August 2020
  • Region: Global
  • 110 pages
  • Zion Market Research
According to the report, the global oncology drug market was valued at USD 104.7 Billion in 2019 and is expected to reach over USD 169.9 Billion by 2026, growing at a CAGR of around 7.2% during the forecast period from 2020 to 2026.

Cancer is a class of chronic illness characterized by uncontrolled cell growth.The common types of cancer are breast cancer, cancer of the lung, colorectal cancer, uterine cancer and cancer of the thyroid.The three main drugs used for cancer are cytotoxic drugs, targeted drugs, and hormonal drugs based on their mechanism of action. The investment dynamics has increased which has propelled the growth for oncology rug market.

Oncology Drug Market: Overview

Oncology is a branch of therapeutic science that study malignancy and treatment and prevention of malignancy. Segments of oncology include radiation oncology (the use of radiation therapy to treat cancer), medical oncology (the use of chemotherapy, hormone therapy and other drugs to treat cancer), and surgical oncology (the use of surgeries to treat cancer).

Cancer is the uncontrolled growth of abnormal cells anywhere in an individual’s body. These cells are termed as tumor cells or malignant cells. Frequently, cancer cells can detach from this original mass of cells, travel along the blood and lymph systems, and lodge in other organs where they can repeat the uncontrolled growth cycle. This process of cancer cells, leaving an area and growing in another area of the body is termed as metastatic spread or metastasis.

Cancer stage is often determined by biopsy results which also helps to determine the cancer type and the extent to which cancer has spread in an individual. Staging also helps doctors to determine treatment protocols.

Oncology Drug Market: Market Dynamics

Major drivers in the oncology drug market include growing prevalence of various types of cancer, increasing demand of biological and targeted drug therapies, technological advancements in the healthcare sector, continuous patent expiry of key cancer drugs, rise in need for R&D activities in cancer, growing concerns over high death rates due to cancer and the rising impact of biosimilars.

The threat of failure and the adverse effects of cancer drug therapy; particularly chemotherapy, strict government regulations, the high cost of drug development is expected to hinder the growth of the global oncology drugs market over the forecast period.

Oncology treatments are rapidly evolving with the latest innovations emerging from immunotherapy research, thus creating new grounds for R&D for the competing firms, cancer vaccines is also seeing a genetic engineering of living immune cells and reinfusing them into cancer patients, re-emerged when combined with checkpoint inhibitors, yet another kind of immunotherapy, is swiftly advancing. The recent discovery of genes linked to ovarian cancer risk (RAD51C and RAD51D0), new pancreatic cancer susceptibility genes (CDKN2A, BRCA1/2, PALB2), and the discovery that many cases of pediatric cancer are associated with hereditary gene mutations, may lead to new kinds of targeted therapies.

Segmentation based on the Therapeutic Modals:
  • Chemotherapy
  • Targeted therapy
  • Immunotherapy
  • Hormonal therapy
  • Others
Segmentation based on the Cancer Type:
  • Breast cancer
  • Blood cancer
  • Prostate cancer
Gastrointestinal tract cancer
  • Skin cancer
  • Lung cancer
  • Others
Segmentation based on Regions:

North America dominates the oncology drug market over the forecast period, attributed to high presence of the cancer drugs development companies in the U.S. Additionally, high disposable incomes of consumers and compulsory health insurance cover for life-threatening diseases leads to increasing the affordability of cancer treatment in the U.S. Europe is the second largest revenue generating region in oncology drugs market over the forecast period. The research for cancer drugs in developing economies including Asia Pacific, Latin America, and the Middle East and Africa is emerging with the focus towards the development of biosimilars. The prevalence of various cancer types is high in developing countries which generates interest for these regions to conduct clinical trials. In addition, the cost of research is low in these regions due to favorable government policies and the availability of a huge population base contributing to the oncology drug market growth in the developing countries. This, in turn, results in the significant growth of oncology drug market in the developing region over the forecast period.

Oncology Drug Market: Competitors

Some of the key players in the global oncology drug market include Johnson & Johnson, Amgen Inc., Eli lilly & Co., GlaxoSmithKline, Roche diagnostics, Merck & Co., Pfizer, Sanofi, and Celgene Corporation, and Novartis AG.

Global Heat Stabilizer Market: Regional Segment Analysis
  • North America
  • The U.S.
  • Europe
  • The UK
  • France
  • Germany
  • The Asia Pacific
  • China
  • Japan
  • India
  • Latin America
  • Brazil
  • The Middle East and Africa
What Reports Provides
  • Full in-depth analysis of the parent market
  • Important changes in market dynamics
  • Segmentation details of the market
  • Former, on-going, and projected market analysis in terms of volume and value
  • Assessment of niche industry developments
  • Market share analysis
  • Key strategies of major players
  • Emerging segments and regional markets
  • Testimonials to companies in order to fortify their foothold in the market.
Note: Product cover images may vary from those shown
  • Chapter 1 Preface
    • 1.1 Report Description
    • 1.1 Report Scope
  • Chapter 2 Research Methodology
    • 2.1 Research Methodology
    • 2.2 Secondary Research
    • 2.3 Primary Research
    • 2.4 Models
      • 2.4.1 Company Share Analysis Model
      • 2.4.2 Revenue Based Modelling
    • 2.5 Research Limitations
  • Chapter 3 Executive Summary
    • 3.1 Global Onculogy Drug Market, 2016 – 2026 (USD Million)
    • 3.2 Global Onculogy Drug Market: Snapshot
  • Chapter 4 Onculogy Drug Market – Industry Analysis
    • 4.1 Introduction
    • 4.2 Market Drivers
      • 4.2.1 Driving Factor 1 Analysis
      • 4.2.2 Driving Factor 2 Analysis:
    • 4.3 Market Restraints
      • 4.3.1 Restraining Factor Analysis
    • 4.4 Market Opportunities
      • 4.4.1 Market Opportunity & Use-case Analysis
      • 4.4.2 Use – Cases for Onculogy Drug
    • 4.5 Porter’s Five Forces Analysis
    • 4.6 COVID 19 Impact Analysis
      • 4.6.1.1 Impact on Product Development and technology Adoption
      • 4.6.1.2 Gap Analysis
  • Chapter 5 Investment Proposition Analysis
    • 5.1 Global Onculogy Drug Market Attractiveness, By Therapeutic Models
    • 5.2 Global Onculogy Drug Market Attractiveness, By Cancer Type
    • 5.3 Global Onculogy Drug Market Attractiveness, By Region
  • Chapter 6 Competitive Landscape
    • 6.1 Company Market Share Analysis - 2019
      • 6.1.1 Global Onculogy Drug Market: Company Market Share, 2019
    • 6.2 Strategic Developments
    • 7.1 Global Onculogy Drug Market Overview: By Therapeutic Models
      • 7.1.1 Global Onculogy Drug Market Revenue Share, By Therapeutic Models, 2019 & 2026
    • 7.2 Global Onculogy Drug Market Analysis/Overview – By Therapeutic Models
      • 7.2.1 Chemotherapy – Overview/Analysis
      • 7.2.2 Targeted Therapy – Overview/Analysis
      • 7.2.3 Immunotherapy – Overview/Analysis
      • 7.2.4 Hormonal Therapy – Overview/Analysis
      • 7.2.5 Others – Overview/Analysis
    • 7.3 Chemotherapy
      • 7.3.1 Global Onculogy Drug Market for Chemotherapy, Revenue (USD Million) 2016 - 2026
    • 7.4 Targeted Therapy
      • 7.4.1 Global Onculogy Drug Market for Targeted Therapy, Revenue (USD Million) 2016 - 2026
    • 7.5 Immunotherapy
      • 7.5.1 Global Onculogy Drug Market for Immunotherapy, Revenue (USD Million) 2016 - 2026
    • 7.6 Hormonal Therapy
      • 7.6.1 Global Onculogy Drug Market for Hormonal Therapy, Revenue (USD Million) 2016 - 2026
    • 7.7 Others
      • 7.7.1 Global Onculogy Drug Market for Others, Revenue (USD Million) 2016 - 2026
    • 8.1 Global Onculogy Drug Market Overview: By Cancer Type
      • 8.1.1 Global Onculogy Drug Market Revenue Share, By Cancer Type, 2019 & 2026
    • 8.2 Global Onculogy Drug Market Analysis/Overview – By Cancer Type
      • 8.2.1 Breast Cancer – Overview/Analysis
      • 8.2.2 Blood Cancer – Overview/Analysis
      • 8.2.3 Prostate Cancer – Overview/Analysis
      • 8.2.4 Skin Cancer – Overview/Analysis
      • 8.2.5 Lung Cancer – Overview/Analysis
      • 8.2.6 Others – Overview/Analysis
    • 8.3 Breast Cancer
      • 8.3.1 Global Onculogy Drug Market for Breast Cancer, Revenue (USD Million) 2016 - 2026
    • 8.4 Blood Cancer
      • 8.4.1 Global Onculogy Drug Market for Blood Cancer, Revenue (USD Million) 2016 - 2026
    • 8.5 Prostate Cancer
      • 8.5.1 Global Onculogy Drug Market for Prostate Cancer, Revenue (USD Million) 2016 - 2026
    • 8.6 Skin Cancer
      • 8.6.1 Global Onculogy Drug Market for Skin Cancer, Revenue (USD Million) 2016 - 2026
    • 8.7 Lung Cancer
      • 8.7.1 Global Onculogy Drug Market for Lung Cancer, Revenue (USD Million) 2016 - 2026
    • 8.8 Others
      • 8.8.1 Global Onculogy Drug Market for Others, Revenue (USD Million) 2016 - 2026
  • Chapter 9 Onculogy Drug Market – Regional Analysis
    • 9.1 Global Onculogy Drug Market: Regional Overview
      • 9.1.1 Global Onculogy Drug Market Revenue Share, by Region, 2019 & 2026
      • 9.1.2 Global Onculogy Drug Market Revenue, by Region, 2016 – 2026 (USD Million)
    • 9.2 North America
      • 9.2.1 North America Onculogy Drug Market Revenue, 2016 - 2026 (USD Million)
      • 9.2.2 North America Onculogy Drug Market Revenue, by Country, 2016 – 2026 (USD Million)
      • 9.2.3 North America Onculogy Drug Market Revenue, By Therapeutic Models, 2016 – 2026
      • 9.2.4 North America Onculogy Drug Market Revenue, By Cancer Type, 2016 – 2026
      • 9.2.5 U.S.
      • 9.2.6 Canada
    • 9.3 Europe
      • 9.3.1 Europe Onculogy Drug Market Revenue, 2016 - 2026 (USD Million)
      • 9.3.2 Europe Onculogy Drug Market Revenue, by Country, 2016 – 2026 (USD Million)
      • 9.3.3 Europe Onculogy Drug Market Revenue, By Therapeutic Models, 2016 – 2026
      • 9.3.4 Europe Onculogy Drug Market Revenue, By Cancer Type, 2016 – 2026
      • 9.3.5 Germany
      • 9.3.6 France
      • 9.3.7 U.K.
      • 9.3.8 Rest of Europe
    • 9.4 Asia Pacific
      • 9.4.1 Asia Pacific Onculogy Drug Market Revenue, 2016 - 2026 (USD Million)
      • 9.4.2 Asia Pacific Onculogy Drug Market Revenue, by Country, 2016 – 2026 (USD Million)
      • 9.4.3 Asia Pacific Onculogy Drug Market Revenue, By Therapeutic Models, 2016 – 2026
      • 9.4.4 Asia Pacific Onculogy Drug Market Revenue, By Cancer Type, 2016 – 2026
      • 9.4.5 China
      • 9.4.6 Japan
      • 9.4.7 India
      • 9.4.8 Rest of Asia Pacific
    • 9.5 Latin America
      • 9.5.1 Latin America Onculogy Drug Market Revenue, 2016 - 2026 (USD Million)
      • 9.5.2 Latin America Onculogy Drug Market Revenue, by Country, 2016 – 2026 (USD Million)
      • 9.5.3 Latin America Onculogy Drug Market Revenue, By Therapeutic Models, 2016 – 2026
      • 9.5.4 Latin America Onculogy Drug Market Revenue, By Cancer Type, 2016 – 2026
      • 9.5.5 Brazil
      • 9.5.6 Rest of Latin America
    • 9.6 The Middle-East and Africa
      • 9.6.1 The Middle-East and Africa Onculogy Drug Market Revenue, 2016 - 2026 (USD Million)
      • 9.6.2 The Middle-East and Africa Onculogy Drug Market Revenue, by Country, 2016 – 2026 (USD Million)
      • 9.6.3 The Middle-East and Africa Onculogy Drug Market Revenue, By Therapeutic Models, 2016 – 2026
      • 9.6.4 The Middle-East and Africa Onculogy Drug Market Revenue, By Cancer Type, 2016 – 2026
      • 9.6.5 GCC Countries
      • 9.6.6 Rest of Middle-East Africa
  • Chapter 10 Company Profiles
    • 10.1 Johnson & Johnson
      • 10.1.1 Company Overview
      • 10.1.2 Financial Overview
      • 10.1.3 Product portfolio
      • 10.1.4 Business Strategy
      • 10.1.5 Recent Developments
    • 10.2 Amgen Inc.
    • 10.3 Eli Lilly Co.
    • 10.4 GSK
    • 10.5 Roche Diagnostics
    • 10.6 Merck & Co.
    • 10.7 Pfizer
    • 10.8 Sanofi
    • 10.9 Novartis AG
    • 10.10 Celgene Corporation
Note: Product cover images may vary from those shown
Adroll
adroll